OX Receptor

Isoform-selective Products

Signaling Pathway

OX Receptor Signaling Pathway

OX Receptor Products

  • All (9)
  • OX Receptor Antibodies (2)
  • OX Receptor Antagonists (6)
  • OX Receptor Agonist (1)
  • New OX Receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2160 Almorexant HCl Almorexant HCl (ACT-078573) is an orally active, dual orexin receptor antagonist with IC50 of 6.6 nM and 3.4 nM for OX1 and OX2 receptor, respectively. Phase 3.
J Adv Res, 2024, S2090-1232(24)00359-X
bioRxiv, 2024, 2024.07.06.602357
Cell Rep, 2022, 40(5):111153
S7585 SB-334867 SB-334867 is a selective orexin-1 (OX1) receptor antagonist.
J Neuroinflammation, 2020, 17(1):187
Med Sci Monit, 2019, 25:2886-2895
S1545 SB408124 SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor.
Nat Chem Biol, 2017, 13(2):235-242
E0107 EMPA EMPA is a selective OX2 receptor antagonist and binds to human and rat OX2-HEK293 membranes with Kd values of 1.1 and 1.4 nM respectively.
Eur Heart J, 2024, 31:ehae472.
Oxid Med Cell Longev, 2022, 2022:1122494
A2814 Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4, CD134, OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.94 KD.
A2633 Anti-OX2R / CD200R1 Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD.
E4740New TAK-861 TAK-861 is a potent, orally bioavailable agonist of orexin receptor 2 (OX2R), with an EC50 of 2.5 nM in calcium mobilization assays. It induces dose-dependent membrane depolarization in histaminergic neurons within the mouse tuberomammillary nucleus (TMN) with an EC50 of 31.7 nM.
S6726 MK1064 MK1064 is a selective orexin 2 receptor antagonist (2-SORA) with an IC50 of 18 nM.
S6717 TCS-OX2-29 TCX-OX2-29 is a OX2R antagonist (pKi = 7.5) that exhibits >250-fold selectivity for hOX2R compared with hOX1R (IC50s = 40 nM and >10,000 nM, respectively).
A2814 Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4, CD134, OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.94 KD.
A2633 Anti-OX2R / CD200R1 Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD.
S2160 Almorexant HCl Almorexant HCl (ACT-078573) is an orally active, dual orexin receptor antagonist with IC50 of 6.6 nM and 3.4 nM for OX1 and OX2 receptor, respectively. Phase 3.
J Adv Res, 2024, S2090-1232(24)00359-X
bioRxiv, 2024, 2024.07.06.602357
Cell Rep, 2022, 40(5):111153
S7585 SB-334867 SB-334867 is a selective orexin-1 (OX1) receptor antagonist.
J Neuroinflammation, 2020, 17(1):187
Med Sci Monit, 2019, 25:2886-2895
S1545 SB408124 SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor.
Nat Chem Biol, 2017, 13(2):235-242
E0107 EMPA EMPA is a selective OX2 receptor antagonist and binds to human and rat OX2-HEK293 membranes with Kd values of 1.1 and 1.4 nM respectively.
Eur Heart J, 2024, 31:ehae472.
Oxid Med Cell Longev, 2022, 2022:1122494
S6726 MK1064 MK1064 is a selective orexin 2 receptor antagonist (2-SORA) with an IC50 of 18 nM.
S6717 TCS-OX2-29 TCX-OX2-29 is a OX2R antagonist (pKi = 7.5) that exhibits >250-fold selectivity for hOX2R compared with hOX1R (IC50s = 40 nM and >10,000 nM, respectively).
E4740New TAK-861 TAK-861 is a potent, orally bioavailable agonist of orexin receptor 2 (OX2R), with an EC50 of 2.5 nM in calcium mobilization assays. It induces dose-dependent membrane depolarization in histaminergic neurons within the mouse tuberomammillary nucleus (TMN) with an EC50 of 31.7 nM.
E4740New TAK-861 TAK-861 is a potent, orally bioavailable agonist of orexin receptor 2 (OX2R), with an EC50 of 2.5 nM in calcium mobilization assays. It induces dose-dependent membrane depolarization in histaminergic neurons within the mouse tuberomammillary nucleus (TMN) with an EC50 of 31.7 nM.

Choose Selective OX Receptor Inhibitors

Tags: OX Receptor inhibitor|OX Receptor agonist|OX Receptor activator|OX Receptor inducer|OX Receptor antagonist|OX Receptor signaling pathway|OX Receptor assay kit